CA3134174A1 - Jak1 selective kinase inhibitor - Google Patents
Jak1 selective kinase inhibitor Download PDFInfo
- Publication number
- CA3134174A1 CA3134174A1 CA3134174A CA3134174A CA3134174A1 CA 3134174 A1 CA3134174 A1 CA 3134174A1 CA 3134174 A CA3134174 A CA 3134174A CA 3134174 A CA3134174 A CA 3134174A CA 3134174 A1 CA3134174 A1 CA 3134174A1
- Authority
- CA
- Canada
- Prior art keywords
- onh
- amino
- methoxy
- methylpiperazin
- indo1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/083376 | 2019-04-19 | ||
| CN2019083376 | 2019-04-19 | ||
| PCT/CN2020/085338 WO2020211839A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3134174A1 true CA3134174A1 (en) | 2020-10-22 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3134174A Pending CA3134174A1 (en) | 2019-04-19 | 2020-04-17 | Jak1 selective kinase inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12606544B2 (https=) |
| EP (1) | EP3956322B1 (https=) |
| JP (1) | JP7555959B2 (https=) |
| KR (1) | KR20220003537A (https=) |
| CN (1) | CN113710664B (https=) |
| AR (1) | AR118729A1 (https=) |
| AU (1) | AU2020258619C1 (https=) |
| BR (1) | BR112021020964A2 (https=) |
| CA (1) | CA3134174A1 (https=) |
| DK (1) | DK3956322T3 (https=) |
| ES (1) | ES3031576T3 (https=) |
| MX (1) | MX2021012749A (https=) |
| PT (1) | PT3956322T (https=) |
| TW (1) | TWI910107B (https=) |
| WO (1) | WO2020211839A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022111499A1 (zh) * | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| ES2938648T3 (es) * | 2017-01-17 | 2023-04-13 | Astrazeneca Ab | Inhibidores selectivos de JAK1 |
| CA3113732C (en) * | 2018-09-21 | 2023-07-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
-
2020
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619C1/en active Active
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 US US17/604,442 patent/US12606544B2/en active Active
- 2020-04-17 TW TW109112994A patent/TWI910107B/zh active
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022529061A (ja) | 2022-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| EP3956322A4 (en) | 2023-05-03 |
| US20220220096A1 (en) | 2022-07-14 |
| EP3956322A1 (en) | 2022-02-23 |
| ES3031576T3 (en) | 2025-07-09 |
| AU2020258619A1 (en) | 2021-09-16 |
| MX2021012749A (es) | 2021-11-18 |
| WO2020211839A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| CN113710664B (zh) | 2024-01-26 |
| KR20220003537A (ko) | 2022-01-10 |
| AU2020258619C1 (en) | 2026-01-29 |
| AU2020258619B2 (en) | 2025-10-23 |
| TWI910107B (zh) | 2026-01-01 |
| US12606544B2 (en) | 2026-04-21 |
| DK3956322T3 (da) | 2025-06-16 |
| PT3956322T (pt) | 2025-06-04 |
| TW202104215A (zh) | 2021-02-01 |
| AR118729A1 (es) | 2021-10-27 |
| EP3956322B1 (en) | 2025-05-14 |
| BR112021020964A2 (pt) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102720958B1 (ko) | 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물 | |
| EP3956322B1 (en) | Jak1 selective kinase inhibitor | |
| ES2737696T3 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| TWI704152B (zh) | 作為ｊａｋ激酶抑制劑之萘啶化合物 | |
| ES2755355T3 (es) | Derivados de isocromeno como inhibidores de fosfoinosítido 3-quinasas | |
| US10590077B2 (en) | TRPV4 antagonists | |
| JP7646671B2 (ja) | Ｂｔｋ阻害剤 | |
| ES2906956T3 (es) | Derivados de oxepinopirazol como inhibidores de la actividad de PI3-cinasa | |
| RU2818002C2 (ru) | Селективный ингибитор киназы JAK1 | |
| US12527797B2 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| HK40055987A (en) | Jak1 selective kinase inhibitor | |
| ES3041596T3 (en) | Dihydrofuropyridine derivatives as rho- kinase inhibitors | |
| HK40055987B (zh) | Jak1选择性激酶抑制剂 | |
| US11230547B2 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| US20240092791A1 (en) | Dihydrofuropyridine derivatives as rho-kinase inhibitors | |
| BR112016013154B1 (pt) | Compostos derivados de isocromeno como inibidores da fosfoinositídeo 3-quinases, composição farmacêutica e uso compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231227 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250602 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250729 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |